Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.71 |
| ▸ | CTSS | P25774 | 5/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003572 | 1.00 | CTSK (0.71) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL25555628 | 0.89 | CTSS (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL27383483 | 0.88 | CTSS (0.57) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL9788528 | 0.88 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL4470428 | 0.88 | CTSK (0.67) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL7554817 | 0.87 | CTSK (0.56) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL17491018 | 0.87 | CTSS (0.73) | CTSKCTSSCA2CTSLCTSB | |
| SCHEMBL10308397 | 0.85 | CTSK (0.68) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL16710009 | 0.84 | CTSK (0.70) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL8536880 | 0.84 | KMT2A (0.57) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4392417-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| CN-107567438-A | Riluzole prodrug and application thereof | 拜尔哈文制药股份有限公司 | 2018-01-09 | — | — | CN | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-8580852-B2 | 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010123832-A2 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | WO | disclosed |
| CN-1839150-A | Lipopeptide antibacterial derivative composition and application method thereof | MIGENIX INC (CA) | 2006-09-27 | — | — | CN | disclosed |
| US-5037957-A | Oliopeptides of glycine diazomethylketone and valine possibly containing proline, arginine and lucine with protective groups | GRUBB ANDERS (SE) | 1991-08-06 | — | — | US | disclosed |
| EP-0418233-A1 | CYSTEINE PROTEINASE INHIBITOR | GRUBB, Anders (SE) | 1991-03-27 | — | — | EP | disclosed |
| WO-1988010266-A1 | CYSTEINE PROTEINASE INHIBITOR | GRUBB ANDERS (SE) | 1988-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSK 1499/4885CTSS 1265/4885CA2 2189/4885 |
| US-12005047-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA2 2889/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CTSK 1659/4885CTSS 1454/4885CA2 2277/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA2 2889/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA2 2889/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA2 2889/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSK 586/4885CTSS 653/4885CA2 2889/4885 |
| US-20120095096-A1 | 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES | PLA2G2E, PLA2G4A, PLAA | CTSK 2760/4885CTSS 2394/4885CA2 1023/4885 |
| US-20240368158-A1 | KINASE MODULATORS, COMPOSITIONS COMPRISING THE KINASE MODULATOR, AND METHODS OF USING THE SAME | FLT3, PHKG1, LTK | CTSK 559/4885CTSS 2523/4885CA2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.